Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey

摘要: Background: The use of pegylated interferon alpha and ribavirin (PegIFN/RBV) for the retreatment chronic hepatitis C virus (HCV) infection without a sustained virological response (SVR) prior to PegIFN/RBV treatment has resulted in low success rates. Aims: To investigate efficacy safety telaprevir (TVR) combination with patients infected HCV genotypes 1 4 who were previously treated failed achieve SVR. Study Design: Multi-center, retrospective, cross-sectional study. Methods: study included 111 patients: 80 relapsers, 25 null responders, six partial responders treatment. given TVR/PegIFN/RBV 12 weeks, followed by 12-week treatment; results assessed at weeks 4, 12, 24. Treatment was discontinued RNA >1000 IU/mL week or negative but 12. Rapid (RVR), early (EVR), extended rapid (eRVR), 24th evaluated. side effects therapy rates discontinuation investigated. Results: mean age 56.02±9.96 years 45.9% male. Ninety-one percent viral genotype 1, 69.6% interleukin (IL) 28B CT 20.2% cirrhotic. RVR rate 86.3% 56% 50% (p=0.002). EVR those groups 91.3%, 56%, 83.3%, respectively (p<0.001). eRVR 83.8% 48% (<0.001). found be highest relapsers (88.8%); it 66.7% Common fatigue, headache, anorexia, malaise, anemia, pruritus, dry skin, rash, dyspepsia, nausea, pyrexia, stomachache, anorectal discomfort. All treatments due 9.9% patients. Conclusion: High obtained Although frequently observed, low.